12th Annual Congress of the European Society of Gene Therapy

Read, Martin; Spice, Rachel; Parker, Alan L.; Mir, Sohaib; Logan, Ann

doi:10.1517/14712598.5.1.137

Cited by 4 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies showed the importance of let-7's role in a poor outcome of cetuximab-treated metastatic CRC patients [ 102 , 103 ]. Also, let-7a-mediated regulation of K-Ras expression was fi rst described in lung cancer [ 104 ].…”

Section: Micrornas As Drugsmentioning

confidence: 99%

Use of MicroRNAs in Personalized Medicine

Avci

Baran

2013

Methods in Molecular Biology

View full text Add to dashboard Cite

Personalized medicine comprises the genetic information together with the phenotypic and environmental factors to yield healthcare tailored to an individual and removes the limitations of the "one-size-fits-all" therapy approach. This provides the opportunity to translate therapies from bench to clinic, to diagnose and predict disease, and to improve patient-tailored treatments based on the unique signatures of a patient's disease and further to identify novel treatment schedules. Nowadays, tiny noncoding RNAs, called microRNAs, have captured the spotlight in molecular biology with highlights like their involvement in DNA translational control, their impression on mRNA and protein expression levels, and their ability to reprogram molecular signaling pathways in cancer. Realizing their pivotal roles in drug resistance, they emerged as diagnostic targets orchestrating drug response in individualized therapy examples. It is not premature to think that researchers could have the US Food and Drug Administration (FDA)-approved kit-based assays for miRNA analysis in the near future. We think that miRNAs are ready for prime time.

show abstract

Section: Micrornas As Drugsmentioning

confidence: 99%

Use of MicroRNAs in Personalized Medicine

Avci

Baran

2013

Methods in Molecular Biology

View full text Add to dashboard Cite

show abstract

New Strategies for Cardiovascular Gene Therapy: Regulatable Pre-Emptive Expression of Pro-Angiogenic and Antioxidant Genes

Dulak

Загорска

Węgiel

et al. 2006

CBB

View full text Add to dashboard Cite

Cardiovascular diseases are among the major targets for gene therapy. Initially, clinical experiments of gene transfer of vascular endothelial growth factor (VEGF) improved vascularization and prevented the amputation in patients with critical leg ischemia. However, the majority of trials did not provide conclusive results and therefore further preclinical studies are required. Importantly, data indicate the necessity of regulated expression of angiogenic factors, particularly VEGF, to obtain the therapeutic effect. It is also suggested that the combined delivery of two or more genes may improve the formation of mature vasculature and therefore may be more effective in the amelioration of ischemia. Moreover, experimental approaches in animal models displayed the promise of gene transfer modulating the inflammatory processes and oxidant status of the cells. Particularly, the concept of preemptive gene therapy has been tested, and recent studies have demonstrated that overexpression of heme oxygenase-1 or extracellular superoxide dismutase can prevent heart injury by myocardial infarction induced several weeks after gene instillation. The combination of a preemptive strategy with regulated gene expression, using the vectors in which the therapeutic transgene is driven by exogenously or endogenously controllable promoter, offers another modality. However, we hypothesize that regulatable gene therapy, dependent on the activity of endogenous factors, might be prone to limitations owing to the potential disturbance in the expression of endogenous genes. Here, we demonstrated some indications of these drawbacks. Therefore, the final acceptance of these promising strategies for clinical trials requires careful validation in animal experiments.

show abstract

Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer

Sempere¹

2011

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

The promise of personalized medicine is highly dependent on the identification of biomarkers that inform diagnostic decisions and treatment options, as well as on the accurate, rapid and cost-effective detection and interpretation of these biomarkers. miRNAs, which are short noncoding regulatory RNAs, are rapidly emerging as a novel class of biomarkers with a unique set of biological and chemical properties that makes them very appealing candidates for theranostic applications in cancer. Since the utility of some protein-encoding gene biomarkers is already exploited in routine clinical practice, it will be important to identify areas in which miRNAs provide complementary or superior information to these existing (and other translational) biomarkers to enhance the diagnostic, prognostic and predictive power of molecular characterization of tumors. In this article, the challenges and opportunities for integration of miRNA-based assays in the clinical toolkit to improve care and management of patients afflicted with solid tumors will be discussed.

show abstract

12th Annual Congress of the European Society of Gene Therapy

Cited by 4 publications

References 10 publications

Use of MicroRNAs in Personalized Medicine

Use of MicroRNAs in Personalized Medicine

New Strategies for Cardiovascular Gene Therapy: Regulatable Pre-Emptive Expression of Pro-Angiogenic and Antioxidant Genes

Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer

Contact Info

Product

Resources

About